共 50 条
Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
被引:16
|作者:
Musunuru, Kiran
[1
]
机构:
[1] Univ Penn, Cardiovasc Inst, Dept Med, Dept Genet,Perelman Sch Med, Philadelphia, PA 19104 USA
来源:
关键词:
cholesterol;
coronary artery disease;
genetics;
inflammation;
lipoproteins;
triglycerides;
OF-FUNCTION MUTATIONS;
C-REACTIVE PROTEIN;
DENSITY-LIPOPROTEIN CHOLESTEROL;
TRIGLYCERIDE TRANSFER PROTEIN;
HIGH-RISK;
CARDIOVASCULAR-DISEASE;
HEART-DISEASE;
DOUBLE-BLIND;
TARGETING APOLIPOPROTEIN(A);
MENDELIAN RANDOMIZATION;
D O I:
10.1146/annurev-med-080819-044918
中图分类号:
R-3 [医学研究方法];
R3 [基础医学];
学科分类号:
1001 ;
摘要:
Statins, ezetimibe, and PCSK9 inhibitors are currently the standard of care for the prevention and treatment of coronary artery disease. Despite their widespread use, coronary artery disease remains the leading cause of death worldwide, a fact that pleads for the development of new protective therapies. In no small part due to advances in the field of human genetics, many new therapies targeting various lipid traits or inflammation have recently received approval from regulatory agencies such as the US Food and Drug Administration or fared favorably in clinical trials. This wave of new therapies promises to transform the care of patients at risk for life-threatening coronary events.
引用
收藏
页码:447 / 458
页数:12
相关论文